HISTOGEN'S PROPRIETARY TECHNOLOGY PROCESS
Through Histogen’s proprietary technology process that mimics the embryonic environment, including very low oxygen and low gravity conditions, newborn cells develop stem cell markers and become embryonic-like and naturally produce vital proteins and growth factors which are characteristic of young, rapidly developing tissue.
From this process, Histogen extracts two products – an insoluble human extracellular matrix (hECM) and a soluble complex of proteins – with a variety of applications in various markets and segments of the life science industry.
Histogen’s one technology, two products, numerous applications model offers a continuum of product introduction opportunities, from lead applications such as hair regrowth and skincare to longer timeline therapeutic applications including oncology and wound care.
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen’s proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families – ExceltrixTM, Histogen’s human Extracellular Matrix (ECM) and ReGenicaTM, Histogen’s proprietary liquid formula. For more information, please visit http://www.histogeninc.com.